The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
5‐hydroxytryptamine and the pulmonary circulation: receptors, transporters and relevance to pulmonary arterial hypertension
Open accessAbstract
Circulating 5-hydroxytryptamine (5-HT) is produced mainly in the enterochromaffin cells of the intestine. 5-HT is also, however, locally released from pulmonary neuroendocrine cells and neuroepithelial bodies distributed throughout the airways. Secretion of large amounts of 5-HT from these cells occurs in response to airway hypoxia and increased local 5-HT may contribute to secondary pulmonary arterial hypertension [PAH] (Johnson & Georgieff, 1989). Normally, plasma levels of free 5-HT are extremely low as circulating 5-HT is stored within the platelets. Human blood platelets contain a relatively specific uptake mechanism for 5-HT (the 5-HT transporter [5-HTT]) at the plasma membrane, intracellular storage organelles (dense bodies) and a metabolizing enzyme (monoamine oxidase B). The 'Serotonin hypothesis of PAH' was developed in the 1960's after an outbreak of PAH was observed in patients taking aminorex, a diet pill that increases 5-HT availability by inducing platelet release of 5-HT, inhibiting its reuptake and inhibiting monoamine oxidase activity. Since then there has been increasing interest in the role of 5-HT in the development of PAH. Here we review pharmacological evidence that suggests changes in 5-HT availability, 5-HT-induced vasoconstriction, 5-HT-induced mitogenesis and 5-HT transporter activity are associated with the development of PAH. There are major structural and functional differences between the systemic and pulmonary circulations which predict differential pharmacology. In the systemic circulation, 75–80% of vascular resistance is maintained by small muscular arterioles whilst resistance is relatively evenly distributed throughout the normal pulmonary circulation. In man, pulmonary arteries >1 mm i.d. are elastic in nature and essentially similar to large systemic conducting arteries. These pulmonary arteries have well developed internal and external laminae and a less distinct medial layer than that of systemic arteries. Most pulmonary arteries follow, and are adjacent to, the airways. Distal to the respiratory bronchioles the smooth muscle layers are abruptly reduced and the arteries are only partially muscularized or non-muscular (Meyrick & Reid, 1983). These are the vessels most affected by pulmonary hypertension. Vascular tone is a major determinant of pulmonary vascular reactivity to endogenous vasoconstrictors and hypoxia (McMurtry et al., 1977; Barer et al., 1993; MacLean, 1999b). Initial vascular tone is extremely low in the normal lung unlike in the systemic circulation where basal tone is maintained by tonic activity of the sympathetic nervous system. Sympathetic innervation of the pulmonary circulation does exist and its activation has similar effects as in the systemic circulation but this does not contribute to basal vasomotor tone. Pulmonary arteries exhibit a vasoconstrictor response to hypoxic conditions (Von Euler & Liljestrand, 1946) unlike the vasodilator response to hypoxia exhibited by the systemic circulation. In the foetus, this hypoxic pulmonary vassoconstriction (HPV) serves to increase pulmonary vascular resistance and divert the circulation through the ductus arteriosus. The foetal pulmonary circulation therefore only receives ∼10% of the cardiac output unlike the situation after birth where exposure to atmospheric oxygen fully dilates the pulmonary circulation which henceforth receives 100% of the cardiac output. After birth, HPV is an important negative feedback mechanism required for ventilation-perfusion matching. Since its first description the mechanism of HPV has been investigated but still remains largely unsolved. Recent hypotheses include hypoxia-induced inactivation of voltage activated potassium (Kv) channels in the pulmonary circulation (Smirnov et al., 1994; Weir & Archer, 1995). There is great heterogeneity in the phenotype of pulmonary vascular SMCs (Frid et al., 1994). This varies with the size and location of the pulmonary artery. Different phenotypes respond differentially to vasoactive factors and exhibit differential pharmacology. For example, K+ channels are differentially distributed (Michelakis, 1997) and there are cell-specific differences in the endothelin-1 (ET-1) system (Tchekneva et al., 2000). The vasoconstrictor response to ET-1 is mediated by ETA receptors in large pulmonary arteries but by ETB-like receptors in smaller muscular pulmonary arteries (MacLean et al., 1994a; McCulloch et al., 1996). Hence there are many differences between the normal pulmonary and systemic arterial ciculations which should predict differential pharmacology and vascular reactivity. Changes occur in the pulmonary hypertensive lung which further alters pulmonary arterial pharmacology and reactivity. Primary PAH (PPH) is the clinical term used to describe a rare condition associated with progressive elevation in pulmonary arterial pressure (by 10–15 mmHg), associated with pulmonary vascular remodelling, for which no underlying cause can be found. P
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Valvular heart disease associated with fenfluramine-phentermine
Connolly, H. M., Crary, J. L., McGoon, M. D., Hensrud, D. D., Edwards, B. S., Edwards, W. D., & Schaff, H. V. (1997) · New England Journal of Medicine · doi:10.1056/nejm199708283370901 · Cited by 1,632
General involvement of hypoxia-inducible factor 1 in transcriptional response to hypoxia.
Wang, G. L., & Semenza, G. L. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.9.4304 · Cited by 1,468
Appetite-suppressant drugs and the risk of primary pulmonary hypertension
Abenhaim, L., Moride, Y., Brenot, F., Rich, S., Benichou, J., Kurz, X., Higenbottam, T., Oakley, C., Wouters, E., Aubier, M., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199608293350901 · Cited by 1,162
Cited by
Cellular and molecular pathobiology of pulmonary arterial hypertension
Humbert, M., Morrell, N. W., Archer, S. L., Stenmark, K. R., MacLean, M. R., Lang, I. M., Christman, B. W., Weir, E. K., Eickelberg, O., Voelkel, N. F., et al. (2004) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2004.02.029 · Cited by 1,576
Self-citationHypoxia-Induced Pulmonary Vascular Remodeling: Cellular and Molecular Mechanisms
Stenmark, K. R., Fagan, K. A., & Frid, M. G. (2006) · Circulation Research · doi:10.1161/01.res.0000243584.45145.3f · Cited by 1,006
Cellular and Molecular Basis of Pulmonary Arterial Hypertension
Morrell, N. W., Adnot, S., Archer, S. L., Dupuis, J., Lloyd Jones, P., MacLean, M. R., McMurtry, I. F., Stenmark, K. R., Thistlethwaite, P. A., Weissmann, N., et al. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.04.018 · Cited by 819
Self-citationInflammation, Growth Factors, and Pulmonary Vascular Remodeling
Hassoun, P. M., Mouthon, L., Barberà, J. A., Eddahibi, S., Flores, S. C., Grimminger, F., Jones, P. L., Maitland, M. L., Michelakis, E. D., Morrell, N. W., et al. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.04.006 · Cited by 710
Self-citationPulmonary Arterial Hypertension
McLaughlin, V. V., & McGoon, M. D. (2006) · Circulation · doi:10.1161/circulationaha.104.503540 · Cited by 664
Metadata
- Authors
- MacLean, M. R., Herve, P., Eddahibi, S., & Adnot, S.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2000-09
- Volume
- 131
- Issue
- 2
- Pages
- 161-168
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W2035427061
- Cited by
- 232
- References
- 3
- FWCI
- 7.15
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: 5‐hydroxytryptamine and the pulmonary circulation: receptors, transporters and relevance to pulmonary arterial hypertension. https://app.cochat.ai/papers/10.1038/sj.bjp.0703570
- The paper
- MacLean, M. R., Herve, P., Eddahibi, S., & Adnot, S. (2000). 5‐hydroxytryptamine and the pulmonary circulation: receptors, transporters and relevance to pulmonary arterial hypertension. British Journal of Pharmacology. https://doi.org/10.1038/sj.bjp.0703570
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.